The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids


Oun A., Sabogal-Guaqueta A. M. , Galuh S., Alexander A., Kortholt A., Dolga A. M.

NEUROBIOLOGY OF DISEASE, vol.173, 2022 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 173
  • Publication Date: 2022
  • Doi Number: 10.1016/j.nbd.2022.105837
  • Journal Name: NEUROBIOLOGY OF DISEASE
  • Journal Indexes: Science Citation Index Expanded, Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Keywords: LRRK2, Mitochondria, Inflammation, iPSC, ALPHA-SYNUCLEIN, STEM-CELL, DOPAMINERGIC-NEURONS, ENERGY HOMEOSTASIS, KINASE-ACTIVITY, HUMAN BRAIN, DYSFUNCTION, MUTATION, NEURODEGENERATION, OLIGODENDROCYTES

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease affecting elderly people. Pathogenic mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common cause of autosomal dominant PD. LRRK2 activity is enhanced in both familial and idiopathic PD, thereby studies on LRRK2-related PD research are essential for understanding PD pathology. Finding an appropriate model to mimic PD pathology is crucial for revealing the molecular mechanisms underlying disease progression, and aiding drug discovery. In the last few years, the use of human-induced pluripotent stem cells (hiPSCs) grew exponentially, especially in studying neurodegenerative diseases like PD, where working with brain neurons and glial cells was mainly possible using postmortem samples. In this review, we will discuss the use of hiPSCs as a model for PD pathology and research on the LRRK2 function in both neuronal and immune cells, together with reviewing the recent advances in 3D organoid models and microfluidics.